Welcome to BioSeeker Group!

Portfolio Analytics and Planning in the Breast Cancer Pipeline - Change is Around the Corner in a Highly Competitive Market Place

Additional Information

Published Date Apr 26, 2010
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 913
PDF Fact Sheet View Fact Sheet for the report Portfolio Analytics and Planning in the Breast Cancer Pipeline - Change is Around the Corner in a Highly Competitive Market Place in PDF
Format PDF
Publisher BioSeeker Group
Product Line View All Available Cancer Highlights Reports

Availability: In stock

$1,950.00

Quick Overview

This report comprises defined and up to date development strategies for 405 breast cancer drugs within the portfolio of 220 investigators, from Ceased to Marketed. The report extensively analyses 207 identified targets of breast cancer drugs, organized into 193 drug target strategies, and assesses them in breast cancer. Significantly new breast cancer therapies will soon come to challenge old established drugs on the market.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Portfolio Analytics and Planning in the Breast Cancer Pipeline - Change is Around the Corner in a Highly Competitive Market Place.

    To find out more about Portfolio Analytics and Planning in the Breast Cancer Pipeline - Change is Around the Corner in a Highly Competitive Market Place, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Portfolio Analytics and Planning in the Breast Cancer Pipeline - Change is Around the Corner in a Highly Competitive Market Place is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This report comprises defined and up to date development strategies for 405 breast cancer drugs within the portfolio of 220 investigators, from Ceased to Marketed. The report extensively analyses 207 identified targets of breast cancer drugs, organized into 193 drug target strategies, and assesses them in breast cancer. Significantly new breast cancer therapies will soon come to challenge old established drugs on the market. Three out of four target strategies in Phase III and almost nine out of ten in Phase II are novel and innovative in their design. Small molecules and antibodies dominate as compound strategies, however BioSeeker foresees a competitive opening for peptide and protein based drugs to excel.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in breast cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any breast cancer drug to ensure that the optimal market conditions exist by the time the product is commercialized.

1 Executive Summary 3
2 About Cancer Highlights 4
3 Methodologies 6
4 Table of Contents 8
4.1 List of Figures 20
4.2 List of Tables 20
5 Introduction 29
5.1 The Scope of this Report 29
5.2 Definitions 32
5.3 Abbreviations 32
6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment 33
6.1 Drug Repositioning in Oncology 33
6.2 Introduction to Breast Cancer Therapeutic Targets in Oncology 34
6.2.1 Catalytic Activity Targets 37
6.2.2 Cell Adhesion Molecule Activity Targets 47
6.2.3 Chaperone Activity Targets 53
6.2.4 Chemokine Activity Targets 57
6.2.5 Complement Activity Targets 58
6.2.6 Cysteine-type Peptidase Activity Targets 61
6.2.7 Cytokine Activity Targets 65
6.2.8 DNA Binding Targets 71
6.2.9 DNA Repair Protein Targets 74
6.2.10 DNA Topoisomerase Activity Targets 75
6.2.11 DNA-directed DNA Polymerase Activity Targets 79
6.2.12 Extracellular Ligand-Gated Ion Channel Activity Targets 80
6.2.13 Extracellular Matrix Structural Constituent Targets 81
6.2.14 G-protein Coupled Receptor Activity Targets 82
6.2.15 Glutathione Transferase Activity Targets 87
6.2.16 Growth Factor Activity Targets 88
6.2.17 Growth Factor Binding Targets 93
6.2.18 Hormone Activity Targets 94
6.2.19 Ion Channel Activity Targets 95
6.2.20 Isomerase Activity Targets 96
6.2.21 Kinase Activity Targets 97
6.2.22 Kinase Binding Targets 105
6.2.23 Kinase Regulator Activity Targets 107
6.2.24 Ligand-dependent Nuclear Receptor Activity Targets 110
6.2.25 Ligase Activity Targets 112
6.2.26 Lipid Kinase Activity Targets 117
6.2.27 Lipid Phosphatase Activity Targets 125
6.2.28 Metallopeptidase Activity Targets 126
6.2.29 Molecular Function Unknown Targets 128
6.2.30 Motor Activity Targets 137
6.2.31 Oxidoreductase Activity Targets 138
6.2.32 Peroxidase Activity Targets 145
6.2.33 Phosphoric Diester Hydrolase Activity Targets 146
6.2.34 Protein Binding Targets 148
6.2.35 Protein Serine/Threonine Kinase Activity Targets 151
6.2.36 Protein Threonine/Tyrosine Kinase Activity Targets 176
6.2.37 Protein-Tyrosine Kinase Activity Targets 181
6.2.38 Receptor Activity Targets 189
6.2.39 Receptor Binding Targets 201
6.2.40 Receptor Signaling Complex Scaffold Activity Targets 205
6.2.41 Receptor Signaling Protein Serine/Threonine Kinase Activity Targets 208
6.2.42 RNA-directed DNA Polymerase Activity Targets 209
6.2.43 Serine-type Peptidase Activity Targets 210
6.2.44 Structural Constituent of Cytoskeleton Targets 212
6.2.45 Structural Molecule Activity Targets 214
6.2.46 Superoxide Dismutase Activity Targets 216
6.2.47 T cell Receptor Activity Targets 218
6.2.48 Transcription Factor Activity Targets 219
6.2.49 Transcription Regulator Activity Targets 238
6.2.50 Transferase Activity Targets 245
6.2.51 Translation Regulator Activity Targets 247
6.2.52 Transmembrane Receptor Activity Targets 248
6.2.53 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 251
6.2.54 Transporter Activity Targets 284
6.2.55 Voltage-gated Ion Channel Activity Targets 289
6.2.56 Other Targets 290
6.3 The Cancer Genome Project and Breast Cancer Therapeutic Targets 293
6.3.1 Breast Cancer Therapeutic Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 293
6.4 Structure-based Drug Design in Breast Cancer Therapeutics is Stimulated by Available Structure Data on Biological Targets 298
6.5 Target-Target Interactions among Identified Therapeutics Targets in Breast Cancer 303
6.6 The Drug-Target Interactome 308
6.7 Protein Expression Levels of Identified Targets of Breast Cancer Drugs 313
6.8 Pathway Assessment of Breast Cancer Therapeutic Targets 318
6.8.1 Tools for Analysis of Cancer Pathways 319
6.8.2 Pathway Assessment 320
7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Breast Cancer Therapeutic Pipeline? 377
7.1 Terminated Drug Target Profiles of Breast Cancer Drugs 380
7.2 Marketed: New and Unique Drug Target Profiles of Breast Cancer Therapeutics 385
7.3 Phase III Clinical Development: New and Unique Drug Target Profiles of Breast Cancer Therapeutics 388
7.4 Phase II Clinical Development: New and Unique Drug Target Profiles of Breast Cancer Therapeutics 390
7.5 Phase I Clinical Development: New and Unique Drug Target Profiles of Breast Cancer Therapeutics 397
7.6 Preclinical Development: New and Unique Drug Target Profiles of Breast Cancer Therapeutics 401
7.7 No Development Data: New and Unique Drug Target Profiles of Breast Cancer Therapeutics 404
7.8 Development Profiles of All Breast Cancer Drugs in Oncology 406
7.9 The Competition Through Close Mechanistic Approximation of Breast Cancer Therapeutics 434
8 Compound Strategies at Work: Competitive Benchmarking of Breast Cancer Drugs by Compound Strategy 442
8.1 Small Molecules 444
8.1.1 Background 444
8.1.2 Target Profiles of Small Molecular Drugs 445
8.2 Peptide/Protein Drugs 461
8.2.1 Background 461
8.2.2 Target Profiles of Peptide and Protein Drugs 462
8.3 Antibodies and Antibody-like Structures 466
8.3.1 Background 466
8.3.2 Target Profiles of Antibody Drugs 466
8.4 Nucleic Acid Therapies 470
8.4.1 Background 470
8.4.2 Target Profiles of Nucleic Acid Drugs 471
8.5 Cell and Gene Therapy 473
8.5.1 Background 473
8.5.2 Target Profiles of Cell- and Gene Therapy Drugs 474
8.6 Drug Delivery and Nanotechnology 477
8.6.1 Background 477
8.6.2 Target Profiles of Reformulated Drugs 477
8.7 Compound Strategies based on Sub-Cellular Localization of Breast Cancer Drug Targets 480
9 Pipeline and Portfolio Planning: Competitive Benchmarking of Breast Cancer Cancer Therapeutic Pipeline by Investigator 489
9.1 Competitive Fall-Out Assessment 489
9.2 Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change 490
9.3 A&G Pharmaceutical 492
9.4 Abbott 493
9.5 Abiogen 496
9.6 Abraxis BioScience 498
9.7 Access 501
9.8 Adherex 502
9.9 Advaxis 504
9.10 AEgera 506
9.11 Aeterna Zentaris 507
9.12 Affibody 509
9.13 Alchemia 511
9.14 Alethia Biotherapeutics 513
9.15 Alnis Biosciences 514
9.16 AlphaVax 516
9.17 Alseres Pharmaceuticals 518
9.18 Amgen 519
9.19 AngioChem 522
9.20 Antisoma 524
9.21 Aphios 526
9.22 Apthera 530
9.23 Archer Biosciences 532
9.24 Ariad 534
9.25 ArQule 535
9.26 Array BioPharma 537
9.27 Ascend Therapeutics 540
9.28 Astellas 542
9.29 AstraZeneca 543
9.30 Attenuon 551
9.31 AVI BioPharma 552
9.32 Bavarian Nordic 554
9.33 Bayer 556
9.34 Betagenon 560
9.35 Biogen Idec 561
9.36 Bionovo 563
9.37 BioVex 564
9.38 Boehringer Ingelheim 565
9.39 Bristol-Myers Squibb 566
9.40 BTG 575
9.41 Callisto Pharmaceuticals 577
9.42 Cancer Research Technology 579
9.43 Cel-Sci 582
9.44 Cell Genesys 583
9.45 Cell Therapeutics 584
9.46 Celldex Therapeutics 586
9.47 Celsion 588
9.48 Celtic Pharma 590
9.49 Center of Molecular Immunology 591
9.50 Cephalon 592
9.51 ChemGenex Pharmaceuticals 594
9.52 Chemokine Therapeutics 596
9.53 Chiesi 597
9.54 CompleGen 599
9.55 Cyclacel 600
9.56 Cylene Pharmaceuticals 601
9.57 Cynvec 602
9.58 CytImmune Sciences 603
9.59 Cytokinetics 605
9.60 CytRx 606
9.61 Daiichi Sankyo 608
9.62 Dainippon Sumitomo Pharma 610
9.63 Debiopharm 612
9.64 Dendreon 614
9.65 Dong-A 616
9.66 Dongkook Pharm 618
9.67 Douglas 619
9.68 ECI 621
9.69 Eisai 622
9.70 Elan 624
9.71 Elara Pharmaceuticals 625
9.72 Eli Lilly 627
9.73 Endoceutics 632
9.74 Enkam Pharmaceuticals 634
9.75 EntreMed 635
9.76 Enzon 637
9.77 Epeius Biotechnologies 638
9.78 EpiCept 640
9.79 Eucodis 642
9.80 Exelixis 643
9.81 Fresenius 647
9.82 Genentech 649
9.83 Generex 651
9.84 Genmab 653
9.85 Genta 655
9.86 GenVec 656
9.87 Genzyme 657
9.88 Geron 658
9.89 GlaxoSmithKline 660
9.90 Gloucester Pharmaceuticals 664
9.91 GlyTag 665
9.92 Got-a-Gene 666
9.93 Heidelberg Pharma 668
9.94 Hoffmann-La Roche 669
9.95 Hospira 681
9.96 Idera Pharmaceuticals 683
9.97 Immunocore 684
9.98 ImmunoGen 686
9.99 Immunomedics 688
9.100 Immunotope 690
9.101 Immutep 691
9.102 Incyte Corporation 692
9.103 Inex 693
9.104 Infinity Pharmaceuticals 695
9.105 Innate Pharma 696
9.106 InNexus Biotechnology 697
9.107 Inovio 699
9.108 Insmed 700
9.109 Intarcia Therapeutics 701
9.110 Intezyne Technologies 702
9.111 Intradigm 704
9.112 Introgen Therapeutics 705
9.113 Ipsen 707
9.114 Isis Pharmaceuticals 710
9.115 Johnson & Johnson 711
9.116 Kiadis 713
9.117 Kyowa Hakko Kirin 714
9.118 LEAD Therapeutics 717
9.119 Leo 718
9.120 Ligand 719
9.121 Lorus Therapeutics 721
9.122 Marillion Pharmaceuticals 722
9.123 MDRNA 723
9.124 Meda 724
9.125 Medarex 726
9.126 MediGene 727
9.127 MedImmune 729
9.128 Mediolanum 730
9.129 Meiji 731
9.130 Menarini 733
9.131 Merck & Co 735
9.132 Merck KGaA 737
9.133 Micromet 739
9.134 Mologen 742
9.135 NanoMed Pharmaceuticals 744
9.136 Nektar Therapeutics 746
9.137 Nemod Biotherapeutics 747
9.138 NeoPharm 748
9.139 NexGenix Pharmaceuticals 751
9.140 Nidus Laboratories 753
9.141 NIH – The US National Institute of Health 755
9.142 Nippon Kayaku 756
9.143 Non-industrial Sources 757
9.144 Novartis 759
9.145 Novogen 767
9.146 OncoGenex Pharmaceuticals 768
9.147 OncoMune 771
9.148 Onconova 773
9.149 Oncothyreon 775
9.150 Orion Pharma 776
9.151 OSI Pharmaceuticals 778
9.152 Oxford BioMedica 783
9.153 Paladin Labs 785
9.154 PanaGin 786
9.155 Pantarhei Bioscience 787
9.156 PepTcell 789
9.157 Peregrine Pharmaceuticals 791
9.158 Pfizer 792
9.159 Pharmacyclics 802
9.160 PharmaGap 803
9.161 PharmaMar 804
9.162 Pharmexa 806
9.163 PheneX 809
9.164 Philogen 810
9.165 Pierre Fabre 811
9.166 Plexxikon 812
9.167 Pro-Pharmaceuticals 813
9.168 ProStrakan 815
9.169 Protox Therapeutics 816
9.170 PTC Therapeutics 817
9.171 R&R 818
9.172 Radient Pharmaceuticals 820
9.173 Raptor Pharmaceutical 821
9.174 Receptor BioLogix 822
9.175 Regeneron 823
9.176 Regulon 824
9.177 Repros Therapeutics 825
9.178 RESprotect 826
9.179 Samyang 827
9.180 Sanofi-Aventis 831
9.181 Santaris Pharma 836
9.182 Sareum 837
9.183 Savient Pharmaceuticals 839
9.184 Schering-Plough 841
9.185 Selvita 843
9.186 Semafore Pharmaceuticals 844
9.187 Sigma-Tau 845
9.188 SRI International 846
9.189 SuperGen 848
9.190 Supratek Pharma 850
9.191 Taiho 853
9.192 Takeda 855
9.193 Targa Therapeutics 856
9.194 Tau Therapeutics 857
9.195 Taxolog 858
9.196 Telik 861
9.197 Teva 863
9.198 Thallion Pharmaceuticals 865
9.199 Therion Biologics 866
9.200 to-BBB 867
9.201 TopoTarget 869
9.202 Tragara Pharmaceuticals 870
9.203 Transgene 871
9.204 Trion Pharma 872
9.205 Vaccinex 874
9.206 Vernalis 875
9.207 Vion Pharmaceuticals 876
9.208 VioQuest 877
9.209 ViroMed 878
9.210 ViroTarg 880
9.211 Wilex 881
9.212 Wyeth 883
9.213 Xerion 884
9.214 Xoma 885
9.215 Yakult Honsha 886
9.216 YM BioSciences 887
9.217 Zensun 888
9.218 Zhejiang Beta Pharma 889
9.219 Zydus Cadila 890
10 Disclaimer 892
11 Drug Index 893
12 Company Index 905

4.1 List of Figures
Figure 1: Visualization of Target-Target Interactions among Targets of Breast Cancer Drugs 307
Figure 2: The Drug-Protein Interactome of Breast Cancer Drugs - Super Cluster 309
Figure 3: The Drug-Protein Interactome of Breast Cancer Drugs - Smaller Clusters 310
Figure 4: Head-to-Head Targeting Interactome of Breast Cancer Drugs – Larger Clusters 311
Figure 5: Head-to-Head Targeting Interactome of Breast Cancer Drugs – Smaller Clusters 312
Figure 6: Distribution of Compound Types among Breast Cancer Drugs 480
Figure 7: Primary Sub-cellular Localization of Drug Targets 481

4.2 List of Tables
Table 1: Overall Breakdown of the Included Breast Cancer Pipeline by Stage of Development 29
Table 2: Head to Head Target Competition among Breast Cancer Drugs 29
Table 3: Overview of Drug Target Profile Themes 34
Table 4: Terminally Ceased Therapeutic Breast Cancer Targets 35
Table 5: Drug Targets of Breast Cancer Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census 294
Table 6: Identity of Breast Cancer Drug Targets with Available Biological Structures 299
Table 7: Number of Target-Target Interactions among Targets of Breast Cancer Drugs 303
Table 8: Breast Cancer Drug Targets with Available Protein Expression Profiles 313
Table 9: Pathway Summary 320
Table 10: Drug Targets without any Identified Assigned Pathways 320
Table 11: Pathway Profiles According to BioCarta of Breast Cancer Drug Targets 322
Table 12: Pathway Profiles According to KEGG of Breast Cancer Drug Targets 348
Table 13: Pathway Profiles According to NetPath of Breast Cancer Drug Targets 371
Table 14: Number of Drug Target Profiles by their Highest Developmental Stage and Uniqueness 377
Table 15: Top Competitive Target Profiles in Breast Cancer 378
Table 16: Terminated Drug Target Strategies of Breast Cancer Drugs 381
Table 17 New and Unique Breast Cancer Target Strategies Being Marketed 385
Table 18: The Competition Through Close Mechanistic Approximation Between Marketed Drugs in Breast Cancer 386
Table 19: New and Unique Breast Cancer Target Strategies in Phase III Clinical Development 388
Table 20: The Competition Through Close Mechanistic Approximation Between Phase III Drugs in Breast Cancer 389
Table 21: New and Unique Breast Cancer Target Strategies in Phase II Clinical Development 390
Table 22: The Competition Through Close Mechanistic Approximation Between Phase II Drugs in Breast Cancer 393
Table 23 New and Unique Breast Cancer Target Strategies in Phase I Clinical Development 397
Table 24: The Competition Through Close Mechanistic Approximation Between Phase I Drugs in Breast Cancer 399
Table 25: New and Unique Breast Cancer Target Strategies in Preclinical Development 401
Table 26: The Competition Through Close Mechanistic Approximation Between Preclinical Drugs in Breast Cancer 403
Table 27: New and Unique Breast Cancer Target Strategies in Unknown Developmental Stage 404
Table 28: The Competition Through Close Mechanistic Approximation Between Drugs with No Developmental Data in Breast Cancer 405
Table 29: The Progression, Maturity and Competitive Comparison of Target Profiles in Breast Cancer Drug Development 406
Table 30: The Competition Through Close Mechanistic Approximation Among All Drugs in Breast Cancer 434
Table 31: Overview of Compound Strategy Competition Among Breast Cancer Drugs 443
Table 32: Overview of the Competitive Landscape of Small Molecular Breast Cancer Drugs 445
Table 33: The Competition Through Close Mechanistic Approximation between Small Molecule Drugs in Breast Cancer 446
Table 34: Competitive Comparison of Target Profiles of Small Molecule Drugs in Breast Cancer 451
Table 35: Overview of the Competitive Landscape of Peptide Based Drugs in Breast Cancer 462
Table 36: The Competition Through Close Mechanistic Approximation between Peptide Based Drugs in Breast Cancer 462
Table 37: Competitive Comparison of Target Profiles of Peptide Based Drugs in Breast Cancer 463
Table 38: Overview of the Competitive Landscape of Protein Based Drugs in Breast Cancer 464
Table 39: The Competition Through Close Mechanistic Approximation between Protein Based Drugs in Breast Cancer 464
Table 40: Competitive Comparison of Target Profiles of Protein Based Drugs in Breast Cancer 465
Table 41: Overview of the Competitive Landscape of Antibody Drugs in Breast Cancer 466
Table 42: The Competition Through Close Mechanistic Approximation between Antibody Drugs in Breast Cancer 467
Table 43: Competitive Comparison of Target Profiles of Antibody Drugs in Breast Cancer 468
Table 44: Overview of the Competitive Landscape of Nucleic Acid Therapy Drugs in Breast Cancer 471
Table 45: The Competition Through Close Mechanistic Approximation between Nucleic Acid Therapy Drugs in Breast Cancer 471
Table 46: Competitive Comparison of Target Profiles of Nucleic Acid Drugs in Breast Cancer 471
Table 47: Potential Forms of Cell Therapy 473
Table 48: Vectors in Gene Therapy 474
Table 49: Competitive Comparison of Target Profiles of Cell Therapy Based Drugs in Breast Cancer 474
Table 50: Overview of the Competitive Landscape of Gene Therapy based Drugs in Breast Cancer 474
Table 51: The Competition Through Close Mechanistic Approximation between Gene Therapy Drugs in Breast Cancer 475
Table 52: Competitive Comparison of Target Profiles of Gene Therapy Based Drugs in Breast Cancer 475
Table 53:Overview of the Competitive Landscape of Reformulated Drugs in Breast Cancer 477
Table 54: The Competition Through Close Mechanistic Approximation between Reformulated Drugs in Breast Cancer 478
Table 55: Competitive Comparison of Target Profiles of Reformulated Drugs in Breast Cancer 478
Table 56: Compound Strategies based on Sub-Cellular Localization of Breast Cancer Drug Targets 481
Table 57: Summary Table of Changes in the Competitive Landscape of Breast Cancer Drug Development 490
Table 58: A&G Pharmaceutical’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 492
Table 59: Abbott’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 493
Table 60: Abiogen’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 496
Table 61: Abraxis BioScience’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 498
Table 62: Access’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 501
Table 63: Adherex’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 502
Table 64: Advaxis’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 504
Table 65: AEgera’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 506
Table 66: Aeterna Zentaris’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 507
Table 67: Affibody’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 509
Table 68: Alchemia’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 511
Table 69: Alethia Biotherapeutics’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 513
Table 70: Alnis Biosciences’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 514
Table 71: AlphaVax’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 516
Table 72: Alseres Pharmaceuticals’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 518
Table 73: Amgen’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 519
Table 74: AngioChem’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 522
Table 75: Antisoma’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 524
Table 76: Aphios’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 526
Table 77: Apthera’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 530
Table 78: Archer Biosciences’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 532
Table 79: Ariad’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 534
Table 80: ArQule’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 535
Table 81: Array BioPharma’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 537
Table 82: Ascend Therapeutics’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 540
Table 83: Astellas’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 542
Table 84: AstraZeneca’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 543
Table 85: Attenuon’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 551
Table 86: AVI BioPharma’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 552
Table 87: Bavarian Nordic’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 554
Table 88: Bayer’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 556
Table 89: Betagenon’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 560
Table 90: Biogen Idec’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 561
Table 91: Bionovo’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 563
Table 92: BioVex’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 564
Table 93: Boehringer Ingelheim’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 565
Table 94: Bristol-Myers Squibb’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 566
Table 95: BTG’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 575
Table 96: Callisto Pharmaceuticals’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 577
Table 97: Cancer Research Technology’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 579
Table 98: Cel-Sci’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 582
Table 99: Cell Genesys’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 583
Table 100: Cell Therapeutics’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 584
Table 101: Celldex Therapeutics’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 586
Table 102: Celsion’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 588
Table 103: Celtic Pharma’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 590
Table 104: Center of Molecular Immunology’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 591
Table 105: Cephalon’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 592
Table 106: ChemGenex Pharmaceuticals’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 594
Table 107: Chemokine Therapeutics’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 596
Table 108: Chiesi’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 597
Table 109: CompleGen’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 599
Table 110: Cyclacel’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 600
Table 111: Cylene Pharmaceuticals’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 601
Table 112: Cynvec’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 602
Table 113: CytImmune Sciences’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 603
Table 114: Cytokinetics’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 605
Table 115: CytRx’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 606
Table 116: Daiichi Sankyo’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 608
Table 117: Dainippon Sumitomo Pharma’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 610
Table 118: Debiopharm’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 612
Table 119: Dendreon’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 614
Table 120: Dong-A’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 616
Table 121: Dongkook Pharm’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 618
Table 122: Douglas’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 619
Table 123: ECI’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 621
Table 124: Eisai’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 622
Table 125: Elan’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 624
Table 126: Elara Pharmaceuticals’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 625
Table 127: Eli Lilly’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 627
Table 128: Endoceutics’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 632
Table 129: Enkam Pharmaceuticals’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 634
Table 130: EntreMed’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 635
Table 131: Enzon’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 637
Table 132: Epeius Biotechnologies’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 638
Table 133: EpiCept’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 640
Table 134: Eucodis’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 642
Table 135: Exelixis’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 643
Table 136: Fresenius’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 647
Table 137: Genentech’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 649
Table 138: Generex’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 651
Table 139: Genmab’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 653
Table 140: Genta’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 655
Table 141: GenVec’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 656
Table 142: Genzyme’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 657
Table 143: Geron’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 658
Table 144: GlaxoSmithKline’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 660
Table 145: Gloucester Pharmaceuticals’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 664
Table 146: GlyTag’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 665
Table 147: Got-a-Gene’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 666
Table 148: Heidelberg Pharma’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 668
Table 149: Hoffmann-La Roche’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 669
Table 150: Hospira’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 681
Table 151: Idera Pharmaceuticals’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 683
Table 152: Immunocore’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 684
Table 153: ImmunoGen’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 686
Table 154: Immunomedics’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 688
Table 155: Immunotope’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 690
Table 156: Immutep’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 691
Table 157: Incyte Corporation’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 692
Table 158: Inex’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 693
Table 159: Infinity Pharmaceuticals’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 695
Table 160: Innate Pharma’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 696
Table 161: InNexus Biotechnology’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 697
Table 162: Inovio’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 699
Table 163: Insmed’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 700
Table 164: Intarcia Therapeutics’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 701
Table 165: Intezyne Technologies’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 702
Table 166: Intradigm’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 704
Table 167: Introgen Therapeutics’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 705
Table 168: Ipsen’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 707
Table 169: Isis Pharmaceuticals’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 710
Table 170: Johnson & Johnson’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 711
Table 171: Kiadis’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 713
Table 172: Kyowa Hakko Kirin’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 714
Table 173: LEAD Therapeutics’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 717
Table 174: Leo’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 718
Table 175: Ligand’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 719
Table 176: Lorus Therapeutics’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 721
Table 177: Marillion Pharmaceuticals’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 722
Table 178: MDRNA’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 723
Table 179: Meda’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 724
Table 180: Medarex’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 726
Table 181: MediGene’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 727
Table 182: MedImmune’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 729
Table 183: Mediolanum’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 730
Table 184: Meiji’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 731
Table 185: Menarini’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 733
Table 186: Merck & Co’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 735
Table 187: Merck KGaA’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 737
Table 188: Micromet’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 739
Table 189: Mologen’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 742
Table 190: NanoMed Pharmaceuticals’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 744
Table 191: Nektar Therapeutics’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 746
Table 192: Nemod Biotherapeutics’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 747
Table 193: NeoPharm’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 748
Table 194: NexGenix Pharmaceuticals’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 751
Table 195: Nidus Laboratories’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 753
Table 196: NIH’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 755
Table 197: Nippon Kayaku’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 756
Table 198: Non-industrial Sources’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 757
Table 199: Novartis’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 759
Table 200: Novogen’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 767
Table 201: OncoGenex Pharmaceuticals’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 768
Table 202: OncoMune’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 771
Table 203: Onconova’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 773
Table 204: Oncothyreon’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 775
Table 205: Orion Pharma’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 776
Table 206: OSI Pharmaceuticals’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 778
Table 207: Oxford BioMedica’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 783
Table 208: Paladin Labs’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 785
Table 209: PanaGin’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 786
Table 210: Pantarhei Bioscience’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 787
Table 211: PepTcell’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 789
Table 212: Peregrine Pharmaceuticals’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 791
Table 213: Pfizer’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 792
Table 214: Pharmacyclics’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 802
Table 215: PharmaGap’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 803
Table 216: PharmaMar’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 804
Table 217: Pharmexa’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 806
Table 218: PheneX’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 809
Table 219: Philogen’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 810
Table 220: Pierre Fabre’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 811
Table 221: Plexxikon’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 812
Table 222: Pro-Pharmaceuticals’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 813
Table 223: ProStrakan’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 815
Table 224: Protox Therapeutics’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 816
Table 225: PTC Therapeutics’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 817
Table 226: R&R’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 818
Table 227: Radient Pharmaceuticals’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 820
Table 228: Raptor Pharmaceutical’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 821
Table 229: Receptor BioLogix’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 822
Table 230: Regeneron’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 823
Table 231: Regulon’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 824
Table 232: Repros Therapeutics’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 825
Table 233: RESprotect’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 826
Table 234: Samyang’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 827
Table 235: Sanofi-Aventis’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 831
Table 236: Santaris Pharma’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 836
Table 237: Sareum’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 837
Table 238: Savient Pharmaceuticals’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 839
Table 239: Schering-Plough’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 841
Table 240: Selvita’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 843
Table 241: Semafore Pharmaceuticals’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 844
Table 242: Sigma-Tau’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 845
Table 243: SRI International’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 846
Table 244: SuperGen’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 848
Table 245: Supratek Pharma’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 850
Table 246: Taiho’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 853
Table 247: Takeda’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 855
Table 248: Targa Therapeutics’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 856
Table 249: Tau Therapeutics’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 857
Table 250: Taxolog’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 858
Table 251: Telik’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 861
Table 252: Teva’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 863
Table 253: Thallion Pharmaceuticals’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 865
Table 254: Therion Biologics’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 866
Table 255: to-BBB’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 867
Table 256: TopoTarget’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 869
Table 257: Tragara Pharmaceuticals’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 870
Table 258: Transgene’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 871
Table 259: Trion Pharma’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 872
Table 260: Vaccinex’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 874
Table 261: Vernalis’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 875
Table 262: Vion Pharmaceuticals’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 876
Table 263: VioQuest’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 877
Table 264: ViroMed’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 878
Table 265: ViroTarg’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 880
Table 266: Wilex’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 881
Table 267: Wyeth’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 883
Table 268: Xerion’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 884
Table 269: Xoma’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 885
Table 270: Yakult Honsha’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 886
Table 271: YM BioSciences’ Included Breast Cancer Drug Pipeline and Competitive Fall-Out 887
Table 272: Zensun’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 888
Table 273: Zhejiang Beta Pharma’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 889
Table 274: Zydus Cadila’s Included Breast Cancer Drug Pipeline and Competitive Fall-Out 890

This report includes 220 investigators plus their collaborators:
A&G Pharmaceutical
Abbott
Abiogen
Abraxis BioScience
Access
Adherex
Advaxis
AEgera
Aeterna Zentaris
Affibody
Alchemia
Alethia Biotherapeutics
Alnis Biosciences
AlphaVax
Alseres Pharmaceuticals
Amgen
AngioChem
Antisoma
Aphios
Apthera
Archer Biosciences
Ariad
ArQule
Array BioPharma
Ascend Therapeutics
Astellas
AstraZeneca
Attenuon
AVI BioPharma
Bavarian Nordic
Bayer
Betagenon
Biogen Idec
Bionovo
BioVex
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Callisto Pharmaceuticals
Cancer Research Technology
Cell Genesys
Cell Therapeutics
Celldex Therapeutics
Cel-Sci
Celsion
Celtic Pharma
Center of Molecular Immunology
Cephalon
ChemGenex Pharmaceuticals
Chemokine Therapeutics
Chiesi
CompleGen
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytokinetics
CytRx
Daiichi Sankyo
Dainippon Sumitomo Pharma
Debiopharm
Dendreon
Dong-A
Dongkook Pharm
Douglas
ECI
Eisai
Elan
Elara Pharmaceuticals
Eli Lilly
Endoceutics
Enkam Pharmaceuticals
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Eucodis
Exelixis
Fresenius
Genentech
Generex
Genmab
Genta
GenVec
Genzyme
Geron
GlaxoSmithKline
Gloucester Pharmaceuticals
GlyTag
Got-a-Gene
Heidelberg Pharma
Hoffmann-La Roche
Hospira
Idera Pharmaceuticals
Immunocore
ImmunoGen
Immunomedics
Immunotope
Immutep
Incyte Corporation
Inex
Infinity Pharmaceuticals
Innate Pharma
InNexus Biotechnology
Inovio
Insmed
Intarcia Therapeutics
Intezyne Technologies
Intradigm
Introgen Therapeutics
Ipsen
Isis Pharmaceuticals
Johnson & Johnson
Kiadis
Kyowa Hakko Kirin
LEAD Therapeutics
Leo
Ligand
Lorus Therapeutics
Marillion Pharmaceuticals
MDRNA
Meda
Medarex
MediGene
MedImmune
Mediolanum
Meiji
Menarini
Merck & Co
Merck KGaA
Micromet
Mologen
NanoMed Pharmaceuticals
Nektar Therapeutics
Nemod Biotherapeutics
NeoPharm
NexGenix Pharmaceuticals
Nidus Laboratories
NIH
Nippon Kayaku
Novartis
Novogen
OncoGenex Pharmaceuticals
OncoMune
Onconova
Oncothyreon
Orion Pharma
OSI Pharmaceuticals
Oxford BioMedica
Paladin Labs
PanaGin
Pantarhei Bioscience
PepTcell
Peregrine Pharmaceuticals
Pfizer
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
PheneX
Philogen
Pierre Fabre
Plexxikon
Pro-Pharmaceuticals
ProStrakan
Protox Therapeutics
PTC Therapeutics
R&R
Radient Pharmaceuticals
Raptor Pharmaceutical
Receptor BioLogix
Regeneron
Regulon
Repros Therapeutics
RESprotect
Samyang
Sanofi-Aventis
Santaris Pharma
Sareum
Savient Pharmaceuticals
Schering-Plough
Selvita
Semafore Pharmaceuticals
Sigma-Tau
SRI International
SuperGen
Supratek Pharma
Taiho
Takeda
Targa Therapeutics
Tau Therapeutics
Taxolog
Telik
Teva
Thallion Pharmaceuticals
Therion Biologics
to-BBB
TopoTarget
Tragara Pharmaceuticals
Transgene
Trion Pharma
Vaccinex
Vernalis
Wilex
Vion Pharmaceuticals
VioQuest
ViroMed
ViroTarg
Wyeth
Xerion
Xoma
Yakult Honsha
YM BioSciences
Zensun
Zhejiang Beta Pharma
Zydus Cadila
This report includes 405 breast cancer drugs. From Ceased to Marketed.
A shortlist of drugs included are:
anastrozole
bevacizumab
BSI-201
capecitabine
catumaxomab
denosumab
docetaxel
doxifluridine
doxorubicin
epirubicin
everolimus
exemestane
fadrozole
formestane
fulvestrant
goserelin
interferon
irinotecan hydrochloride
lapatinib ditosylate
lasofoxifene
letrozole
leuprorelin
mitoxantrone
neratinib
Nudoxa
paclitaxel
pazopanib hydrochloride
pertuzumab
pirarubicin
raloxifene hydrochloride
ramucirumab
Stimuvax
sunitinib malate
tamoxifen
tegafur + uracil
toremifene citrate
trastuzumab
trilostane
triptorelin pamoate
TS-1

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Portfolio Analytics and Planning in the Breast Cancer Pipeline - Change is Around the Corner in a Highly Competitive Market Place.
    To find out more about Portfolio Analytics and Planning in the Breast Cancer Pipeline - Change is Around the Corner in a Highly Competitive Market Place, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Portfolio Analytics and Planning in the Breast Cancer Pipeline - Change is Around the Corner in a Highly Competitive Market Place is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Cancer Highlights' category:


Therapeutic Peptides in Oncology - Favorable Conditions But Where to Commercialize?
This report is an important part of creating and implementing a market development plan for any cancer therapeutic peptide drugs to ensure that the optimal market conditions exist by the time the product is commercialized. Learn More


Portfolio Analytics and Planning in the Breast Cancer Pipeline - Change is Around the Corner in a Highly Competitive Market Place
This report comprises defined and up to date development strategies for 405 breast cancer drugs within the portfolio of 220 investigators, from Ceased to Marketed. The report extensively analyses 207 identified targets of breast cancer drugs, organized into 193 drug target strategies, and assesses them in breast cancer. Significantly new breast cancer therapies will soon come to challenge old established drugs on the market. Learn More

Other selected research from the 'Oncology' category:


Competitive Outlook on Lung Cancer Drug Development - The Missing Handbook to New Product Planning and Portfolio Planning
This report is an important part of creating and implementing a market development plan for any lung cancer therapeutic drugs to ensure that the optimal market conditions exist by the time the product is commercialized. Learn More


Triple Analysis: Prostate Cancer, Cancer Vaccines and Peptides
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Prostate Cancer), one mechanism/target/effect area (Cancer Vaccines) and one compound specific area (Peptides). Learn More